Drug Trial Radar · NCT07724366
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Sep 2, 2026
Primary completion
Sep 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group. The study aims to evaluate the efficacy and safety of once-daily oral TQH3906 capsules (24 mg) in adult participants with moderate to severe plaque psoriasis. TQH3906 is a highly selective TYK2 allosteric inhibitor targeting the JH2 domain, which blocks the IL-23 and Type I interferon inflammatory pathways. Approximately 400 eligible participants aged 18-75 years will be enrolled. Participants will be stratified based on prior biologic use and randomized in a 2:2:1 ratio to the TQH3906 group, the deucravacitinib active control group, or the placebo group. The trial includes a screening period, a 16-week double-blind controlled treatment phase, a 36-week open-label extension phase (during which all participants will receive TQH3906), and a 4-week safety follow-up after the last dose. The co-primary endpoints are the proportion of participants achieving sPGA 0/1 and PASI 90 response at Week 16. Secondary endpoints include improvements in scalp, nail, and palmoplantar psoriasis, Dermatology Life Quality Index (DLQI), long-term safety, and steady-state pharmacokinetic parameters. This study will collect comprehensive efficacy and safety data over 52 weeks to support the New Drug Application (NDA) for TQH3906 for the treatment of plaque psoriasis.
Conditions
- Psoriasis
Interventions
TQH3906 capsulesDrug
TQH3906 Capsules is an inhibitor that targets tyrosine kinase 2 (TYK2).
Deucravacitinib tablets 6 mgDrug
Deucravacitinib tablet is an inhibitor that targets tyrosine kinase 2 (TYK2).
TQH3906 Capsules placeboDrug
No pharmacologically active substance
Deucravacitinib tablets placeboDrug
No pharmacologically active substance
Primary outcomes
What the sponsor says the trial is designed to measure.
- static Physician's Global Assessment (sPGA)Time frame: Baseline up to 16 weeks
- Psoriasis Area and Severity Index (PASI)Time frame: Baseline up to 16 weeks
Locations
45 sites in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
The First Affiliated Hospital of Chongqing Medical University 。
Chongqing, Chongqing Municipality, China · Not yet recruiting
Chongqing Traditional Chinese Medicine Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China · Recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Not yet recruiting
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China · Not yet recruiting
Hainan Fifth People's Hospital
Haikou, Hainan, China · Not yet recruiting
Affiliated Hospital of Chengde Medical University
Chengde, Hebei, China · Recruiting
Shijiazhuang Traditional Chinese Medicine Hospital
Shijiazhuang, Hebei, China · Not yet recruiting
Heilongjiang Provincial Hospital
Harbin, Heilongjiang, China · Recruiting
The Second Affiliated Hospital of Henan University of science and technology
Luoyang, Henan, China · Not yet recruiting
Puyang Oilfield General Hospital
Puyang, Henan, China · Not yet recruiting
Zhengzhou Central Hospital
Zhengzhou, Henan, China · Not yet recruiting
The First Peopel's Hospital of Zhengzhou
Zhengzhou, Henan, China · Not yet recruiting
Jingzhou Central Hospital
Jingzhou, Hubei, China · Recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China · Not yet recruiting
The First People's Hospital of Lianyungang
Lianyungang, Jiangsu, China · Not yet recruiting
Chinese Academy of Medical Sciences Hospital for Skin Diseases
Nanjing, Jiangsu, China · Withdrawn
Nantong Cancer Hospital
Nantong, Jiangsu, China · Not yet recruiting
Suzhou Municipal Hospital
Suzhou, Jiangsu, China · Recruiting
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China · Recruiting
The Second Hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
Zhongyi Northeast International Hospital Co., Ltd.
Shengyang, Liaoning, China · Recruiting
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Shenyang Seventh People's Hospital (Shenyang Hospital of Integrated Traditional Chinese and Western Medicine, Shenyang Dermatology Hospital)
Shenyang, Liaoning, China · Withdrawn
Central Hospital Affiliated to Shenyang Medical College
Shenyang, Liaoning, China · Not yet recruiting
The First People's Hospital of Xining
Xining, Qinghai, China · Not yet recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Not yet recruiting
Qilu Hospital Dezhou Branch of Shandong University (Dezhou People's Hospital)
Dezhou, Shandong, China · Recruiting
Jining No.1 People'S Hospital
Jining, Shandong, China · Not yet recruiting
Qingdao Municipal Hospital
Qingdao, Shandong, China · Not yet recruiting
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Not yet recruiting
The Second People's Hospital of ChangZhi
Changzhi, Shanxi, China · Not yet recruiting
Suining Central Hospital
Suining, Sichuan, China · Recruiting
Gerneral Hospital of Ningxia Medical Univercity
Yinchuan, The Ningxia Hui Autonomous Region, China · Not yet recruiting
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.